Estimation of pH effect on the structure and stability of kinase domain of human integrin-linked kinase

2018 ◽  
Vol 37 (1) ◽  
pp. 156-165 ◽  
Author(s):  
Sunayana Begum Syed ◽  
Mohd Shahbaaz ◽  
Sabab Hassan Khan ◽  
Saurabha Srivastava ◽  
Asimul Islam ◽  
...  
2018 ◽  
Vol 111 ◽  
pp. 208-218 ◽  
Author(s):  
Sunayana Begum Syed ◽  
Faez Iqbal Khan ◽  
Sabab Hasan Khan ◽  
Saurabha Srivastava ◽  
Gulam Mustafa Hasan ◽  
...  

2001 ◽  
Vol 152 (5) ◽  
pp. 1007-1018 ◽  
Author(s):  
Christos G. Zervas ◽  
Stephen L. Gregory ◽  
Nicholas H. Brown

Integrin-linked kinase (ILK) was identified by its interaction with the cytoplasmic tail of human β1 integrin and previous data suggest that ILK is a component of diverse signaling pathways, including integrin, Wnt, and protein kinase B. Here we show that the absence of ILK function in Drosophila causes defects similar to loss of integrin adhesion, but not similar to loss of these signaling pathways. ILK mutations cause embryonic lethality and defects in muscle attachment, and clones of cells lacking ILK in the adult wing fail to adhere, forming wing blisters. Consistent with this, an ILK–green fluorescent protein fusion protein colocalizes with the position-specific integrins at sites of integrin function: muscle attachment sites and the basal junctions of the wing epithelium. Surprisingly, mutations in the kinase domain shown to inactivate the kinase activity of human ILK do not show any phenotype in Drosophila, suggesting a kinase-independent function for ILK. The muscle detachment in ILK mutants is associated with detachment of the actin filaments from the muscle ends, unlike integrin mutants, in which the primary defect is detachment of the plasma membrane from the extracellular matrix. Our data suggest that ILK is a component of the structure linking the cytoskeleton and the plasma membrane at sites of integrin-mediated adhesion.


2018 ◽  
Vol 117 ◽  
pp. 1252-1263 ◽  
Author(s):  
Sunayana Begum Syed ◽  
Faez Iqbal Khan ◽  
Sabab Hasan Khan ◽  
Saurabha Srivastava ◽  
Gulam Mustafa Hasan ◽  
...  

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1944-P
Author(s):  
DAVID A. CAPPEL ◽  
AMBRA POZZI ◽  
ROY ZENT ◽  
DAVID WASSERMAN

Diabetes ◽  
1992 ◽  
Vol 41 (4) ◽  
pp. 521-526 ◽  
Author(s):  
S. Cocozza ◽  
A. Porcellini ◽  
G. Riccardi ◽  
A. Monticelli ◽  
G. Condorelli ◽  
...  

2019 ◽  
Vol 11 (1) ◽  
pp. 27-33
Author(s):  
I Dmytrenko ◽  
J Minchenko ◽  
I Dyagil

The chronic myeloid leukemia (CML) development is associated with the formation of the BCR/ABL1 fusion gene and the BCR/ABL1 protein with increased tyrosine kinase activity. Despite the high efficiency of targeted therapy, up to 30% of patients do not respond on such therapy i.e. are primary resistant. The presence of BCR/ABL1 kinase domain mutations is considered to be one of the reasons of tyrosin kinase inhibitors resistance. To evaluate the frequency of BCR/ABL1 kinase domain mutations in Ukrainian cohort of CML patients with primary resistance to imatinib therapy, we retrospectively studied BCR/ABL1 kinase domain mutations in peripheral blood of 107 CML patients. The nucleotide sequence was determined by direct sequencing by Sanger. Mutations were reported in 45 of 107 (41.7%) CML patients. Two mutations at a time were revealed in 8 patients. So a total of 53 mutations were found out. Among them 49 were missense-mutations and 4 - deletions of different regions of the BCR/ABL1 kinase domain gene. The missense-mutations F359I/V (12 patients), T315I (8 patients) and G250E (6 patients) were most common. By localization, the mutations majority (23 of 53) was in the P-loop, 10 mutations - in the contact site, 13 mutations - in the catalytic domain and 6 – in the A-loop. Of the detected mutations, 26 (49%) resulted in a disruption of the hydrogen bond between BCR/ABL1-tyrosine kinase and imatinib. Significant reduction in overall survival was found in patients with BCR/ABL1 kinase domain mutations compared with patients with wild-type of BCR/ABL1 gene (p=0.018). The estimated 3-year overall survival was 83.4% (95% CI: 77.0%-89.8%) and 94.3% (95% CI: 91.0%-97.3%), respectively. Therefore, mutations of the BCR/ABL1 kinase domain are one of the mechanisms of primary resistance in CML patients on imatinib therapy. The occurrence of BCR/ABL1 gene mutations impairs the prognosis of imatinib therapy response.


Sign in / Sign up

Export Citation Format

Share Document